Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.
Actively Recruiting
Researchers are evaluating brenipatide, a drug given as a subcutaneous injection, compared to a placebo to understand its effects and safety in adults with moderate-to-severe Alcohol Use Disorder AUD. The study is a Phase 3, multicenter, randomized, double-blind trial sponsored by Eli Lilly and Company. The trial aims to assess changes in drinking patterns over a period of up to 56 weeks. Participants receive escalating doses of the study drug or placebo administered by subcutaneous injection. The study includes two experimental periods with LY3537031 and a placebo group. Participants will self-inject the study intervention, keep diaries, and complete questionnaires throughout the trial. The trial design includes random assignment to one of the study groups, and treatment is monitored over the full 56 weeks. During the study, participants will attend regular visits to monitor their alcohol consumption using the Timeline Followback method, assess alcohol cravings with the Penn Alcohol Craving Scale, and evaluate health outcomes including body weight and quality of life measures. Researchers will also study the drugs pharmacokinetics and the presence of anti-drug antibodies. Participation lasts about 56 weeks, with ongoing safety and efficacy assessments throughout this period.
Actively Recruiting
Researchers are studying chronic migraine, a condition causing moderate to severe headaches often on one side of the head, sometimes with nausea, vomiting, and sensitivity to light or sound. This trial evaluates how well the medicine atogepant works compared to a placebo in preventing chronic migraine in participants aged 12 to 17 years. The study also monitors adverse events to assess safety. Participants will be randomly assigned to receive either oral atogepant tablets or placebo once daily for 12 weeks. This double-blind study means neither the participants nor the doctors know who receives the medicine or placebo. Following the treatment, participants will be observed for an additional 4 weeks. During the study, participants will visit hospitals or clinics regularly for assessments. They will complete daily diaries, undergo medical evaluations, blood tests, side effect checks, and questionnaires. The main outcomes include tracking adverse events and changes in monthly migraine days, along with measures of headache days, medication use, and quality of life over approximately 16 weeks.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the study drug Seltorexant compared with a placebo in adults and elderly participants with major depressive disorder MDD, a common mood disorder marked by persistent sadness and loss of interest. This Phase 3 study includes a double-blind treatment phase to measure improvement in depressive symptoms specifically in participants with moderate-to-severe insomnia symptoms. The study also aims to assess long-term safety and tolerability of Seltorexant in an open-label treatment phase. During the double-blind phase, participants will take either a Seltorexant tablet or a matching placebo once daily for 42 days. Those who qualify for the open-label phase will continue taking Seltorexant daily for up to 6 months. The study compares the two groups to understand how well Seltorexant works alone in treating MDD. Participants will undergo clinical assessments including depression rating scales, sleep disturbance questionnaires, and safety evaluations such as vital signs, laboratory tests, electrocardiograms, and suicidality ratings. Researchers will also monitor withdrawal symptoms and sexual functioning during the open-label phase. The total participation duration may extend over several months to evaluate both efficacy and long-term safety outcomes.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating ibuzatrelvir to determine its effectiveness and safety in treating adults and adolescents aged 12 and older who have COVID-19 but are not hospitalized. The study focuses on individuals at high risk of progressing to severe illness. Participants will be randomly assigned to receive either ibuzatrelvir or a placebo, alongside standard care as available locally, with the study lasting approximately six months. Participants will receive either ibuzatrelvir tablets or placebo tablets orally every 12 hours for five days. This is a randomized, double-blind, phase 3 study comparing the investigational drug to placebo. The study allows co-administration of locally available standard treatments. The treatment period is followed by monitoring to assess outcomes related to COVID-19 progression and symptom resolution. During the study, participants will be observed for emergency department visits, hospitalizations, mortality, symptom resolution, and viral load changes over 28 days and up to 24 weeks. Researchers will collect data on medical events, including cardiovascular, renal, and pulmonary complications, as well as Long COVID symptoms. Safety is monitored through adverse event tracking. Overall participation lasts about six months with multiple assessments during this time.
Actively Recruiting
Researchers are conducting a Phase 2 randomized, double-masked, vehicle-controlled study to evaluate the safety and effectiveness of DFL24498 topical ophthalmic solution compared to a vehicle solution in adults with dry eye disease. Approximately 417 participants aged 18 years or older will be enrolled across multiple sites in the US. The study aims to understand how the treatment affects dry eye symptoms and eye health over 16 weeks. Participants will be randomly assigned to receive either DFL24498 or a vehicle solution, both administered as one drop in each eye four times daily for 12 weeks. The study includes three periods within the total 16 weeks, including treatment and follow-up phases. The treatments are applied topically to the eyes under controlled conditions to compare their effects. During the study, participants will undergo assessments such as corneal fluorescein staining using the National Eye Institute scale, symptom evaluations with the Symptom Assessment in Dry Eye questionnaire, tear production tests, and conjunctival staining. Safety will be monitored through reports of adverse events up to week 14. Visual acuity and other ocular measurements will be regularly checked to monitor treatment impact and participant health throughout the study.
Actively Recruiting
Researchers are evaluating LPCN 1154A as a possible treatment for postpartum depression PPD in women with severe symptoms. This phase 3 trial aims to find out if LPCN 1154A can reduce depressive symptoms and how well it is tolerated, including potential side effects. Participants receive either oral LPCN 1154A tablets or placebo tablets for 48 hours. The study is randomized and blinded to compare these two groups in parallel. The treatment phase lasts for 48 hours. During the study, participants will be assessed for changes in depression severity using the Hamilton Depression Rating Scale HAM-D from baseline to hour 60, along with other measures at hour 12 and day 30. Safety and side effects are monitored throughout. The participation spans from screening through treatment and follow-up assessments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of SPN-821, a novel oral drug, as an additional treatment for adults with major depressive disorder MDD. This phase 2, multicenter, randomized, double-blind, placebo-controlled study focuses on adults diagnosed with MDD who continue to experience symptoms despite stable antidepressant therapy. The study aims to assess improvements in depression severity using standardized rating scales. Participants are randomly assigned to receive either SPN-821 at a dose of 2400 mg three 800 mg tablets or matching placebo tablets, both administered twice a week alongside their current antidepressant medication. The study includes a 2-week screening period to confirm eligibility, followed by a 4-week treatment period where participants receive the assigned study tablets. After completing treatment, participants undergo a safety follow-up phone call one week later to monitor any ongoing effects. During the study, participants will have their depression symptoms evaluated using the Montgomery-sberg Depression Rating Scale MADRS and Clinical Global Impression-Severity CGI-S scale at baseline and Day 29. Safety assessments and monitoring occur throughout the trial and during the follow-up call. Overall, the study participation lasts approximately 7 weeks including screening, treatment, and follow-up to understand the impact of SPN-821 on depressive symptoms and safety in adults with MDD.
1-10 of 15
1